Orchard Looks toward Harvesting Expanded Gene Therapy Pipeline

February 15, 2019

It was about ten months ago that Orchard Therapeutics acquired the gene therapy portfolio of GSK, expanding its pipeline and giving it its first approved therapy. We spoke to Orchard CEO Mark Rothera about his company’s approach to gene therapy, its pipeline, and what he sees as the biggest challenges as Orchard moves towards commercializing its therapies.G

Stay Connected

Sign up for updates straight to your inbox.